Available online at www.sciencedirect.com
SCIENCE DIRECT®
ELSEVIER
Bioorganic & Medicinal Chemistry Letters 14 (2004) 1057
Bioorganic & Medicinal Chemistry Letters

Erratum

Erratum to "Synthesis of potent and selective 2-azepanone inhibitors of human tryptase" Biorg. Med. Chem. Lett. 14 (2004) 309☆

Guohua Zhao,* Scott A. Bolton, Chet Kwon, Karen S. Hartl, Steven M. Seiler, William A. Slusarchyk, James C. Sutton and Gregory S. Bisacchi

The Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA

The Publisher regrets that the final sentence of the abstract of the above communication contained an error. The abstract should have read as shown below.

Abstract—The serine protease tryptase has been associated with a broad range of allergic and inflammatory diseases and, in particular, has been implicated as a critical mediator of asthma. The inhibition of tryptase therefore has the potential to be a valuable therapy for asthma. The synthesis, employing solution phase parallel methods, and SAR of a series of novel 2-azepanone tryptase inhibitors are presented. A member of this series, **8t**, was identified as a potent inhibitor of human tryptase ($IC_{50} = 38$ nM) with selectivity ≥ 330-fold versus related serine proteases (trypsin, plasmin, uPA, tPA, APC, alpha-thrombin, and FXa).

☆DOI of original article: 10.1016/j.bmcl.2003.11.016
* Corresponding author. Tel.: +1-609-818-5553; fax: +1-609-818-3450; e-mail: guohua.zhao@bms.com

0960-894X/$ - see front matter © 2003 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2004.01.006